Protocol › Age criteria · Last reviewed 2026-05-16
Age criteria and Tanner stages
Summary
The original Dutch Protocol set thresholds at Tanner stage 2 (about 11–12 years) for puberty suppression, 16 for cross-sex hormones and 18 for surgery. The Endocrine Society guideline of 2017 maintained these benchmarks but allowed hormones to begin before age 16 in selected cases, with documented consent of the patient and parents.
1. Tanner stages
The Tanner stages (1962) describe the progression of sexual maturation. The Dutch Protocol uses the Tanner stage as a criterion for starting GnRH agonists:
| Tanner | Feature girls | Feature boys | Age (mean) |
|---|---|---|---|
| 1 | Prepubertal | Prepubertal | < 10–11 |
| 2 | Beginning breast development (thelarche) | Testicular volume 4 ml+ | 10–12 |
| 3 | Further breast development, pubic hair | Voice change begins | 12–13 |
| 4 | Breast development almost complete | Facial hair | 13–15 |
| 5 | Adult | Adult | 15+ |
2. Original age thresholds
| Intervention | Minimum criterion | Source |
|---|---|---|
| GnRH agonist | Tanner 2 (~12 years) | Delemarre 2006 |
| Cross-sex hormones | 16 years | Delemarre 2006 |
| Surgery | 18 years | Delemarre 2006 |
3. Adjustments under Endocrine Society 2017
The Endocrine Society in its revised guideline (2017) suggested that there may be "compelling reasons" to start cross-sex hormones before the age of 16 in some adolescents (as summarised in WPATH SOC-8: source).1 This relaxation was criticised by various later authors as a deviation from the original Dutch design; see WPATH SOC and the Dutch Protocol.
4. Application in later international practice
In the UK, the 2011 early intervention study recruited patients aged 12-15 with inclusion criteria in line with the original Dutch protocol; the Cass Review calls it the only formal attempt to replicate the Dutch approach.2 The Cass Review (2024) writes that the approach was later extended to a broader group of adolescents who would not have met the inclusion criteria of the original Dutch study (source). Finland (COHERE 2020) and the UK have restricted medical treatment of minors since 2020; the Cass Review notes that the Finnish and Swedish guidelines recommend medical treatment, in the absence of evidence, only within a research framework (source).
Critical note
The age thresholds were set in a protocol whose evidence base is limited. The York systematic review for the Cass Review (2024) found limited or inconsistent evidence on the effects of puberty suppression (source), and SBU (2022) found the evidence insufficient to assess the effects of hormone treatment in adolescents (source).3
See also
- Original protocol description: Delemarre 2006
- How the thresholds relate to the phases: Three treatment phases
- WPATH relaxations: WPATH SOC
- Stricter international application: COHERE Finland, Cass Review
- UK deviation from Dutch criteria: Tavistock GIDS
- People register — Cohen-Kettenis, Delemarre, de Vries.
- International comparison — age thresholds per country.
- Timeline — protocol development chronologically.
- FAQ · Glossary · For parents.
Footnotes
- Hembree WC, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons. J Clin Endocrinol Metab. 2017;102(11):3869–903.
- Cass H. Independent review of gender identity services for children and young people: final report. NHS England; April 2024.
- SBU. Hormone treatment of children and adolescents with gender dysphoria. Stockholm; 2022. Report 342.